Trash collection fees to increase residential utility bills starting July 1
May 19—Utility bills in Newton will see an increase on July 1. The Newton City Council this past month approved a new fee schedule for solid waste and recycling collection following a new contract with Dodd's Trash Hauling and Recycling. The increase amounts to $3.39 per month for each household in town.
Earlier this year, the city distributed requests for proposals to waste management companies, seeking bids for collections services consistent with the existing contract. Three businesses reached out to the city, including local provider Dodd's Trash Hauling and Recycling, which was the clear favorite.
Back then it was noted a new contract would result in higher rates for residents no matter which waste management company was chosen. Currently, residents pay $15.16 per month for waste collection services. The new contract would increase that monthly rate for residential units to $18.55 per month.
Included in the new five-year contract with Dodd's is an annual rate adjustment tied to the Consumer Price Index for All Urban Consumers (CPI-U). The rate covers solid waste and recycling, landfill tipping fees, recycling tipping fees, leaf bag collection and Christmas tree collection.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Mortgage lenders raise rates amid uncertainty over BoE interest rate cuts
Many of the major lenders raised their mortgage rates this week, amid uncertainty over the pace of future interest rate cuts by the Bank of England. The average rate for a two-year fixed mortgage stands at 4.89%, while five-year fixed deals average 5.09%, according to data from Uswitch. Comments by Bank of England governor Andrew Bailey at a cross-party Treasury select committee session on Tuesday over the impact of US president Donald Trump's tariffs on policymaking cast more doubt over the central bank's pace of rate cuts. Bailey said that while the interest rate "path remains downwards, but how far and how quickly is now shrouded in a lot more uncertainty, frankly.' The Bank of England has cut interest rates from 4.5% to 4.25% in early May, meaning the average homeowner on a tracker mortgage will see their monthly repayments fall by nearly £29, after the quarter-point snip to the base rate. However, the primary inflation measure, the Consumer Price Index (CPI), stood at 3.5% in the 12 months to April, a higher-than-expected increase from the previous month. That means price increases are moving away from the BoE's 2% target. This week, no major lender cut rates, with the majority hiking mortgages for first-time buyers as the market moves away from the mini price war that pushed deals deep into under-4% territory. HSBC (HSBA.L) has a 4.01% rate for a five-year deal, which is up from the previous week. For those with a Premier Standard account with the lender, this rate is 3.98%. Looking at the two-year options, the lowest rate is 3.96% on a Premier Standard account with a £999 fee, slightly higher from the previous week. Both cases assume a 60% loan-to-value (LTV) mortgage, meaning buyers need to have at least 40% for a deposit. HSBC offers 95% LTV deals, meaning you only need to save for a 5% deposit. However, the rates are much higher, with a two-year fix at 5.05% or 4.89% for a five-year fix. This is because their financial situation and deposit size determine the rate someone can get. The larger the deposit, the lower the LTV, allowing buyers to access better deals because lenders consider them less risky. NatWest's (NWG.L) five-year deal is 3.99% with a £1,495 fee, which is unchanged from last week. The cheapest two-year fix deal is 3.94%, which is also unchanged from last week. You'll need at least a 40% deposit to qualify for the rates in both cases. At Santander (BNC.L), a five-year fix is 4.08% for first-time buyers, higher than the previous 3.93%. It has a £999 fee, assuming a 40% deposit. Read more: Average first-time buyers in London need almost £140,000 for a deposit For a two-year deal, customers can also secure a 4.01% offer, with the same £999 fee, higher than the previous 3.90%. Barclays (BARC.L) was the first among major lenders to bring back under-4% deals and currently has a five-year fix at 3.99%, which is slightly higher than 3.89% last week. For "premier" clients, this rate dips to 3.98%. The lowest for two-year mortgage deals is 3.97%, which is also up on 3.87% last week. Barclays has launched a mortgage proposition to help new and existing customers access larger loans when purchasing a home. The initiative, known as Mortgage Boost, enables family members or friends to effectively "boost" the amount that can be borrowed toward a property without needing to lend or gift money directly or provide a larger deposit. Read more: Best credit card deals of the week Under the scheme, a borrower's eligibility for a mortgage can increase significantly by including a family member or friend on the application. For example, an individual with a £37,500 annual income and a £30,000 deposit might traditionally be able to borrow up to £168,375, enabling them to purchase a home priced at around £198,375. However, with Mortgage Boost, the total borrowing potential can rise substantially if a second person, such as a parent, joins the application. In this case, if the second applicant also earns £37,500 a year, the combined income could push the borrowing limit to £270,000, enabling the buyer to afford a home worth up to £300,000. Nationwide (NBS.L) offers a five-year fix at 4.24%, with a £999 fee and a 40% deposit and was down from 4.34% last week. Nationwide offers a two-year fixed rate for home purchase at 4.04% with a £999 fee — also for borrowers with a 40% deposit. Again, down from 4.34% in the previous week. The lender has announced it is changing the eligibility criteria for its mortgage scheme, which allows people to borrow up to six times their income. The minimum income required to take out a Helping Hand mortgage has been reduced to £35,000 — meaning more people will be eligible for the scheme. The minimum income requirement for joint applications will remain at £55,000. Helping Hand mortgages enable people to borrow up to six times their income, meaning potential homeowners can borrow 33% more compared to Nationwide's standard lending at 4.5 times income. Halifax, the UK's biggest mortgage lender, offers a five-year rate of 4.03% (also 60% LTV). The lender, owned by Lloyds (LLOY.L), offers a two-year fixed rate deal at 4%, with a £999 fee for first-time buyers. Read more: How to negotiate house prices It also offers a 10-year deal with a mortgage rate of 4.78%. The lender has announced the launch of a new 1.5-year fixed-rate remortgage product in response to growing demand among borrowers for shorter-term deals. Shorter-term fixes offer certainty over monthly payments while allowing households to switch to a new deal sooner to take advantage of lower rates. As providers start hiking rates, prospective homeowners are quickly running out of good options. HSBC's (HSBA.L) 3.98% is currently the cheapest deal for five-year fixes and for two-year fixes at 3.96%, though access requires a hefty 40% deposit. The average UK house price is £273,427, so a 40% deposit equals about £120,000. A growing number of homeowners in the UK are opting for 35-year or longer mortgage terms, with a significant rise in older borrowers stretching their repayment periods well into their 70s. Read more: UK house prices rise in May as higher wages, low unemployment boost market Lender April Mortgages offers buyers the chance to borrow up to seven times their income on loans fixed for five to 15 years. Both those buying alone and those buying with others can apply for the mortgage. As part of the independent Dutch asset manager DMFCO, the company offers interest rates starting at 5.15% and an application fee of £195. Skipton Building Society has also said it would allow first-time buyers to borrow up to 5.5 times their income to help more borrowers get on the housing ladder. Leeds Building Society is increasing the maximum amount that first-time buyers can potentially borrow as a multiple of their earnings with the launch of a new mortgage range. Aspiring homeowners with a minimum household income of £40,000 may now be able to borrow up to 5.5 times their earnings. Mortgage holders and borrowers have faced record-high repayments in recent years, as the Bank of England's base rate has been passed on by banks and building societies. According to UK Finance, 1.3 million fixed mortgage deals are set to end in 2025. Many homeowners will hope the Bank of England acts quickly to cut rates more aggressively. At the same time, savers will likely root for rates to remain at or near their current levels. Read more: Best credit card deals of the week UK mortgage approvals drop for third month in a row How next week's spending review could impact your financesError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
BofA: Bank of Canada in no rush to ease despite dovish hints
-- Bank of America (NYSE:BAC) Securities said the Bank of Canada's decision to hold its policy rate at 2.75% reflects a wait-and-see approach amid persistent inflation and geopolitical trade uncertainties. The central bank's June 4 announcement kept rates unchanged, in line with expectations, while highlighting 'some unexpected firmness in recent inflation data' and ongoing concerns over U.S. tariffs. BoC Governor Tiff Macklem noted, 'There was a clear consensus to hold policy unchanged as we gain more information.' The central bank's stance suggests it is prioritizing stability while awaiting further data on inflation and growth momentum. Carlos Capistran, economist at BofA Securities, said the Bank's statement and press conference indicated a slightly more dovish tilt, pointing to a willingness to ease policy if economic conditions deteriorate. Macklem remarked that 'members thought there could be a need for a reduction in the policy rate if the economy weakens… and cost pressures on inflation are contained,' signaling potential future cuts. Still, Capistran emphasized the BoC's caution in rushing to cut rates, particularly given sticky core inflation readings. 'Underlying inflation could be a bit firmer than we thought,' Macklem acknowledged during the Q&A, reinforcing the Bank's stance to assess incoming data closely before making changes. Capistran expects the BoC to hold its policy rate at 2.75% at the July meeting and begin cutting rates in the fall. BofA forecasts three 25bp reductions in September, October, and December, which would take the benchmark rate to 2.00% by year-end. Market reaction in the rates complex was notably dovish, with Canadian yields declining across the curve. Capistran said the move validated BofA's tactical positioning, and the firm has since closed its pay June BoC OIS trade at target. In currency markets, USD/CAD slid below 1.37 to a new 2025 low after softer U.S. ISM services data compounded the BoC's caution. Capistran said the pair's near-term direction will be shaped by labor reports from both countries, with a stronger-than-expected Canadian print potentially extending recent CAD gains. Capistran remains skeptical of current market pricing, which implies roughly a 50% chance of a July rate cut. 'We see the probability of a cut as currently overpriced,' he argued, noting that two CPI and two labor reports still lie ahead before the BoC's next policy decision. Related articles BofA: Bank of Canada in no rush to ease despite dovish hints Citadel's Griffin: cost of U.S. default insurance is "unfathomable" Tariffs, oil prices, and a stronger Loonie drag Canada's April exports down 10.8% Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced a new partial response (PR) was identified in a patient after 20 months of treatment in its Phase 2 THIO-101 clinical trial evaluating ateganosine (THIO), sequenced with Regeneron's immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy. A partial response is defined as a decrease in tumor size of at least 30%. 'The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment. Extended-term responses like this are not often seen in heavily pretreated patients in hard-to-treat diseases such as NSCLC, where the prognosis for the advanced-stage of the disease is typically poor,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'We confirmed this response with a second scan, and we are highly confident that ateganosine could become an outstanding therapeutic alternative for third-line NSCLC patients.' THIO-101 third line (3L) data cutoff from May 15, 2025, showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine in parts A and B of the trial. At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival. Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months. 1 MAIA has announced the trial design for an expansion of its THIO-101 pivotal Phase 2 trial in NSCLC to assess overall response rates (ORR) in advanced NSCLC patients receiving third line (3L) therapy who were resistant to previous CPI treatment and chemotherapy. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries. 1
